Advanced search in
Projects
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
1 Projects, page 1 of 1

  • Canada
  • European Commission
  • 2018
  • 2020

  • Open Access mandate for Publications
    Funder: EC Project Code: 777450
    Overall Budget: 9,127,320 EURFunder Contribution: 4,498,930 EUR
    Partners: UCB Pharma (Belgium), Eli Lilly and Company Limited, VUA, SYNAPSE RESEARCH MANAGEMENT PARTNERS SL, GRT, EATG, MERCK SHARP & DOHME CORP, ALEXION, TEAM - IT RESEARCH SL, UOXF...

    PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed processes and tools for three key decision-making points (research priority setting, design of clinical trials and early dialogue) will be developed by consensus. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a stakeholder-tailored set of metrics to measure the impact of PE. PARADIGM will deliver to the community, recommendations and tools to support the implementation of PE, leveraging pre-existing resources. These will address capacity and capability questions, managing potential conflict of interest, the compensation of individuals and organisations, and the ethics of engagement. A targeted communication, dissemination and engagement strategy will promote the endorsement of the outputs for their integration in existing structures. PARADIGM will develop a strategy for sustaining the long-term implementation of PE resources aimed at structuring and supporting the community. This will be a game-changer, addressing fundamental gaps and creating real assets to ensure the sustainability of the PE ecosystem in the years to come. PARADIGM has a common vision and values-base, and is a highly innovative, consensus-oriented, and experienced consortium, comprising pan-European leaders in patient engagement, academia, SMEs, health professionals, pharmaceutical and biotech companies, pharmaceutical corporate associations, and representatives of competent authorities, all bringing complementary know-how to partner with industry, and a strong commitment to transform patient engagement in Europe.

Advanced search in
Projects
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
1 Projects, page 1 of 1
  • Open Access mandate for Publications
    Funder: EC Project Code: 777450
    Overall Budget: 9,127,320 EURFunder Contribution: 4,498,930 EUR
    Partners: UCB Pharma (Belgium), Eli Lilly and Company Limited, VUA, SYNAPSE RESEARCH MANAGEMENT PARTNERS SL, GRT, EATG, MERCK SHARP & DOHME CORP, ALEXION, TEAM - IT RESEARCH SL, UOXF...

    PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed processes and tools for three key decision-making points (research priority setting, design of clinical trials and early dialogue) will be developed by consensus. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a stakeholder-tailored set of metrics to measure the impact of PE. PARADIGM will deliver to the community, recommendations and tools to support the implementation of PE, leveraging pre-existing resources. These will address capacity and capability questions, managing potential conflict of interest, the compensation of individuals and organisations, and the ethics of engagement. A targeted communication, dissemination and engagement strategy will promote the endorsement of the outputs for their integration in existing structures. PARADIGM will develop a strategy for sustaining the long-term implementation of PE resources aimed at structuring and supporting the community. This will be a game-changer, addressing fundamental gaps and creating real assets to ensure the sustainability of the PE ecosystem in the years to come. PARADIGM has a common vision and values-base, and is a highly innovative, consensus-oriented, and experienced consortium, comprising pan-European leaders in patient engagement, academia, SMEs, health professionals, pharmaceutical and biotech companies, pharmaceutical corporate associations, and representatives of competent authorities, all bringing complementary know-how to partner with industry, and a strong commitment to transform patient engagement in Europe.